비증식당뇨망막병증에서 Calcium Dobesilate가 시력 및 황반두께에 미치는 영향

Effects of Calcium Dobesilate on Visual Acuity and Macular Thickness in Nonproliferative Diabetic Retinopathy

Purpose: This study aimed to evaluate the effect of calcium dobesilate uptake on visual acuity (VA) and macular thickness by optical coherence tomography (OCT) of eyes with non-proliferative diabetic retinopathy (NPDR) in comparison with bilberry dried extract. Methods: Thirty-six eyes of 36 patients diagnosed with NPDR without macular edema and who were treated with calcium dobesilate for more than 6 months were enrolled in the calcium dobesilate (CAD) group. VA, diabetic retinopathy grade, central macular thickness (CMT), and total macular volume (TMV) at baseline and at the 3- and 6-month follow-up examinations were analyzed retrospectively. The matched patients treated with bilberry dried extract were selected and compared as the control group. Results: The CMT and TMV values were 282.14 ± 31.86, 277.96 ± 31.13, and 281.18 ± 30.41 μm and 8.79 ± 0.58, 8.68 ± 0.59, and 8.73 ± 0.60 ㎣ in the CAD group at baseline and at the 3- and 6-month follow-up, respectively. The TMV had decreased significantly at the 3-month follow-up (p = 0.027); however, the TMV at the 6-month follow-up and the VA and TMV at the 3- and 6-month follow-ups showed no differences from the baseline levels (all p > 0.05). In the control group, no significant changes in VA or in CMT were observed at 3 and 6 months after treatment compared to the baseline (all p > 0.05). Furthermore, no significant difference in CMT on OCT was observed between the two groups at all time points (all p > 0.05). Conclusions: In NPDR patients without macular edema, CAD uptake had no significant effect on VA or macular thickness until 6 months after treatment.